duloxetine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

Nov 1, 2006 → Feb 1, 2008

NCT ID

NCT00401258

About duloxetine

duloxetine is a approved stage product being developed by Eli Lilly for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00401258. Target conditions include Irritable Bowel Syndrome.

What happened to similar drugs?

6 of 20 similar drugs in Irritable Bowel Syndrome were approved

Approved (6) Terminated (1) Active (14)

✅Ramosetron + PlaceboAstellas PharmaApproved

✅Bacillus clausii + MetronidazoleSanofiApproved

✅Iberogast® and Iberogast® NBayerApproved

✅LinaclotideIronwood PharmaceuticalsApproved

✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

🔄YM060 + PlaceboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01391221	Approved	UNKNOWN	Jul 1, 2011	Aug 1, 2013	Major Depression
NCT01363284	Pre-clinical	Completed	Jun 1, 2010	Aug 1, 2012	Diabetes
NCT01089621	Approved	Withdrawn	Mar 1, 2010	Aug 1, 2010	Fibromyalgia
NCT01051466	Approved	Completed	Jan 1, 2010	Mar 1, 2013	Major Depressive Disorder
NCT00989157	Phase 3	Completed	Sep 1, 2009	Nov 1, 2012	Bariatric Surgery
NCT01074151	Pre-clinical	Completed	Jul 1, 2009	Jul 26, 2021	Pregnancy
NCT00889369	Approved	UNKNOWN	May 1, 2009	Jun 1, 2012	Major Depressive Disorder
NCT01754493	Approved	Completed	Dec 1, 2008	Dec 1, 2014	Major Depression
NCT01028352	Pre-clinical	Completed	Oct 1, 2008	Oct 1, 2011	Breast Cancer
NCT00696774	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Depressive Disorder, Major
NCT00532480	Approved	Completed	Sep 1, 2007	Apr 1, 2009	Major Depression
NCT00529789	Phase 2	Completed	Aug 1, 2007	Sep 1, 2008	Major Depressive Disorder
NCT00696293	Approved	Completed	May 1, 2007	Apr 1, 2010	Major Depressive Disorder
NCT00517985	Approved	Completed	Feb 1, 2007	Jun 1, 2008	Major Depressive Disorder
NCT00398632	Approved	Terminated	Nov 1, 2006	Apr 1, 2009	Depression
NCT00401258	Approved	Completed	Nov 1, 2006	Feb 1, 2008	Irritable Bowel Syndrome
NCT00438971	Approved	Completed	Aug 1, 2006	Jan 1, 2009	Panic Disorder
NCT00531895	Approved	Completed	Apr 1, 2006	Mar 1, 2007	Major Depression
NCT00322621	Approved	Completed	Apr 1, 2006	Oct 1, 2007	Diabetic Neuropathies
NCT01035073	Approved	Completed	Apr 1, 2006	May 1, 2009	Major Depressive Disorder

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	35
YM060 + Placebo	Astellas Pharma	Phase 3	40
Ramosetron + Placebo	Astellas Pharma	Approved	43
Ramosetron + Placebo	Astellas Pharma	Approved	43
YM060	Astellas Pharma	Phase 3	40
YM060 + placebo	Astellas Pharma	Phase 2	35
YM060	Astellas Pharma	Phase 3	40
linaclotide + Placebo	Astellas Pharma	Phase 3	40
Ramosetron	Astellas Pharma	Pre-clinical	26
YM060	Astellas Pharma	Phase 2	35
ONO-2952 + Placebo comparator	Ono Pharmaceutical	Phase 2	27
ONO-2952 + ONO-2952 Matching Placebo	Ono Pharmaceutical	Phase 2	35
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)	AbbVie	Phase 3	40
25mg Eluxadoline + 100mg Eluxadoline	AbbVie	Phase 3	47
Eluxadoline + Placebo	AbbVie	Phase 2	42
Placebo + Linaclotide	AstraZeneca	Phase 3	40
Tegaserod	Novartis	Pre-clinical	26
DNK333	Novartis	Phase 2	35
SMS995 + Placebo	Novartis	Phase 1	29
DNK333 + Placebo	Novartis	Phase 2	35